home / stock / slncf / slncf short
Short Information | Silence Therapeutics Ord (OTCMKTS:SLNCF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 29,972 |
Total Actual Volume | 58,630 |
Short Trends | |
---|---|
Cover Days | 6 |
Short Days | 11 |
No Change Days | 3 |
Averages | |
---|---|
Average Short Volume | 1,499 |
Average Short Percentage | 56.43% |
Is there a SLNCF Short Squeeze or Breakout about to happen?
See the SLNCF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-18-2024 | $8.5 | $7.6 | $8.5 | $7.5 | 2,020 | 200 | 9.9% |
07-17-2024 | $8.45 | $7 | $8.5 | $7 | 8,534 | 3,104 | 36.37% |
07-15-2024 | $10.3 | $8.95 | $11 | $8 | 6,456 | 552 | 8.55% |
07-11-2024 | $8.94 | $10.25 | $14.75 | $8.33 | 1,876 | 226 | 12.05% |
07-10-2024 | $9 | $8.95 | $9.25 | $8.95 | 3,250 | 800 | 24.62% |
07-09-2024 | $7.5 | $7.5 | $7.5 | $7.5 | 4,215 | 3,125 | 74.14% |
06-26-2024 | $6.5 | $6.5 | $6.5 | $6.5 | 1,500 | 1,500 | 100% |
05-12-2022 | $5.5 | $5.5 | $5.5 | $5.5 | 1,382 | 100 | 7.24% |
05-04-2022 | $5.5 | $5.5 | $5.51 | $5.5 | 10,220 | 4,050 | 39.63% |
02-09-2022 | $6.8905 | $6.9 | $6.9 | $6.8905 | 2,912 | 2,100 | 72.12% |
01-19-2022 | $7.06 | $7.06 | $7.06 | $7.06 | 600 | 600 | 100% |
11-30-2021 | $6.95 | $7.15 | $7.15 | $6.395 | 2,900 | 2,200 | 75.86% |
07-02-2021 | $8.5 | $8.5 | $8.5 | $8.5 | 100 | 100 | 100% |
06-04-2021 | $9.25 | $8.75 | $9.25 | $8.75 | 200 | 100 | 50% |
05-27-2021 | $9.25 | $9.25 | $9.25 | $9.25 | 110 | 10 | 9.09% |
05-18-2021 | $8.76 | $8.76 | $8.76 | $8.76 | 100 | 100 | 100% |
01-25-2021 | $7.77 | $7.77 | $7.77 | $7.77 | 200 | 200 | 100% |
01-11-2021 | $7.025 | $7.15 | $7.15 | $7.025 | 1,905 | 805 | 42.26% |
01-08-2021 | $7.4 | $7.45 | $7.45 | $7.4 | 10,000 | 10,000 | 100% |
01-07-2021 | $7.15 | $7.15 | $7.15 | $7.15 | 150 | 100 | 66.67% |
News, Short Squeeze, Breakout and More Instantly...
Silence Therapeutics Ord Company Name:
SLNCF Stock Symbol:
OTCMKTS Market:
Silence Therapeutics Ord Website:
Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time Silence Therapeutics plc (“Si...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peoples’ lives by silencing diseases through precision engineered medicines, today announced that it will receive a ...
Study demonstrated highly significant and sustained reductions in Lp(a) to week 48 Data support advancing zerlasiran into phase 3 with 300 mg dose Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotec...